FOURKITES
3.5.2022 10:02:06 CEST | Business Wire | Press release
Leading real-time supply chain visibility platform FourKites ® today announces it meets the standards set by the International Standards Organization (ISO) for ISO 27017 for cloud service security and ISO 27018 for data privacy as part of its ISO 27001 certification. The achievement represents FourKites' ongoing pursuit of the most recent and stringent security standards in the industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220503005646/en/
To qualify, an independent audit committee confirmed that FourKites meets a stringent set of requirements around security and privacy. ISO 27017 provides guidelines for information security controls applicable to and specific to the provisioning and use of cloud services, while ISO 27018 establishes commonly accepted controls and guidelines for implementing measures to protect personally identifiable information (PII) for the public cloud computing environment. Meanwhile, ISO 27001 mandates controls for the establishment, maintenance and certification of an information security management system (ISMS).
“Meeting these standards is a testament to FourKites’ ongoing commitment to go above and beyond when it comes to securing our platform, which ingests more than 250 terabytes of data each month,” said Mathew Elenjickal, FourKites Founder and CEO. “Safe and secure data sharing has tremendous benefits across the supply chain, including more accurate business planning and risk mitigation, higher customer satisfaction and retention, and improved employee morale.”
Adherence to ISO 27017 and 27018 is the latest validation of FourKites’ rigorous security efforts , including its comprehensive General Data Protection Regulation (GDPR ) privacy program, which even applies in regions where it is not required and incorporates the Schrems II ruling.
“Our supply chain customers and partners around the globe can rest assured that FourKites uses the strongest and most secure standards in the industry to protect their valuable data,” added Elenjickal.
FourKites delivers real-time insights to customers around the globe, leveraging patented artificial intelligence based on 150 factors, including weather, traffic and real-time data from GPS, ELD telematics networks, mobile devices, AIS and more. The company offers out-of-the-box dashboards and reports, automated and customisable notifications that leverage geofencing and temperature tracking, and SKU-level visibility to track multimodal shipments, even when they’re split across multiple carriers.
In Spring 2021, FourKites was awarded a patent for its groundbreaking Smart Forecasted Arrival (SFA) solution , which provides companies with highly frequent and accurate estimated times of arrival for over-the-road freight in transit — even when a truck lacks any technology to transmit location data. SFA is now available to FourKites customers globally, extending the benefits of real-time visibility to freight that would otherwise be invisible to modern supply chain management solutions.
About FourKites
FourKites® is the #1 global supply chain visibility platform, extending visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 2.5 million shipments daily across road, rail, ocean, air, parcel and courier, and reaching more than 185 countries, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,000 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220503005646/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
